HMGN3

Summary

HMGN3 (high mobility group nucleosomal binding domain 3, HGNC:12312) is a protein-coding gene on chromosome 6q14.1, encoding High mobility group nucleosome-binding domain-containing protein 3 (Q15651). Binds to nucleosomes, regulating chromatin structure and consequently, chromatin-dependent processes such as transcription, DNA replication and DNA repair.

The protein encoded by this gene binds thyroid hormone receptor beta in the presence of thyroid hormone. The encoded protein, a member of the HMGN protein family, is thought to reduce the compactness of the chromatin fiber in nucleosomes, thereby enhancing transcription from chromatin templates. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. There is a related pseudogene on chromosome 1.

Source: NCBI Gene 9324 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 27 total
• MANE Select transcript: NM_001201363

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12312
Approved symbol	HMGN3
Name	high mobility group nucleosomal binding domain 3
Location	6q14.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000118418
Ensembl biotype	protein_coding
OMIM	604502
Entrez	9324

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 21 protein_coding

ENST00000275036, ENST00000344726, ENST00000620514, ENST00000703810, ENST00000706657, ENST00000706659, ENST00000706660, ENST00000895450, ENST00000895451, ENST00000895452, ENST00000895453, ENST00000895454, ENST00000895455, ENST00000913853, ENST00000913854, ENST00000913855, ENST00000913856, ENST00000913857, ENST00000913858, ENST00000913859, ENST00000957643

RefSeq mRNA: 9 — MANE Select: NM_001201363 NM_001201362, NM_001201363, NM_001318884, NM_001318885, NM_001318886, NM_001318887, NM_001318888, NM_004242, NM_138730

CCDS: CCDS4988, CCDS4989, CCDS75485, CCDS93952

Canonical transcript exons

ENST00000620514 — 7 exons

Exon	Start	End
ENSE00000798002	79202276	79202389
ENSE00000798003	79203580	79203630
ENSE00000798004	79214972	79215022
ENSE00000999529	79208547	79208576
ENSE00000999530	79234546	79234682
ENSE00003475399	79201245	79201726
ENSE00003723579	79202063	79202155

Expression profiles

Bgee: expression breadth ubiquitous, 301 present calls, max score 99.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 81.7367 / max 1047.5441, expressed in 1801 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
74504	81.7367	1801

Top tissues by expression

302 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bronchial epithelial cell	CL:0002328	99.83	gold quality
epithelium of bronchus	UBERON:0002031	99.72	gold quality
bronchus	UBERON:0002185	99.67	gold quality
endothelial cell	CL:0000115	99.65	gold quality
palpebral conjunctiva	UBERON:0001812	99.61	gold quality
right uterine tube	UBERON:0001302	99.53	gold quality
eye	UBERON:0000970	99.50	gold quality
parietal pleura	UBERON:0002400	99.49	gold quality
ventricular zone	UBERON:0003053	99.42	gold quality
mucosa of paranasal sinus	UBERON:0005030	99.42	gold quality
pleura	UBERON:0000977	99.40	gold quality
visceral pleura	UBERON:0002401	99.36	gold quality
hair follicle	UBERON:0002073	99.34	gold quality
germinal epithelium of ovary	UBERON:0001304	99.33	gold quality
epithelium of nasopharynx	UBERON:0001951	99.32	gold quality
nasopharynx	UBERON:0001728	99.30	gold quality
renal glomerulus	UBERON:0000074	99.28	gold quality
metanephric glomerulus	UBERON:0004736	99.25	gold quality
tongue squamous epithelium	UBERON:0006919	99.25	gold quality
pigmented layer of retina	UBERON:0001782	99.21	gold quality
retina	UBERON:0000966	99.18	gold quality
metanephros	UBERON:0000081	99.17	gold quality
nasal cavity mucosa	UBERON:0001826	99.11	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.11	gold quality
cervix squamous epithelium	UBERON:0006922	99.11	gold quality
skin of hip	UBERON:0001554	99.08	gold quality
choroid plexus epithelium	UBERON:0003911	99.07	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.04	gold quality
cranial nerve II	UBERON:0000941	99.01	gold quality
adenohypophysis	UBERON:0002196	98.99	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-MTAB-6701	yes	117.08
E-HCAD-5	yes	61.01
E-MTAB-7316	yes	35.21
E-HCAD-1	yes	32.32
E-MTAB-10287	yes	25.25
E-HCAD-10	yes	17.90
E-MTAB-6678	yes	17.05
E-GEOD-93593	yes	14.16
E-GEOD-130148	yes	12.83
E-CURD-46	yes	12.03
E-MTAB-10042	yes	10.81
E-GEOD-125970	yes	7.32
E-GEOD-75140	no	555.59
E-HCAD-31	no	4.57
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ARX, EBF3, EGR1, ETS2

miRNA regulators (miRDB)

63 targeting HMGN3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-497-3P	99.61	69.71	1990
HSA-MIR-325	99.58	66.55	358
HSA-MIR-217-5P	99.49	69.93	1419
HSA-MIR-5009-3P	99.45	69.43	1341

Literature-anchored findings (GeneRIF, showing 4)

• loss of HMGN3 impairs glucose-stimulated insulin secretion and leads to a diabetic phenotype. (PMID:19651901)
• The SNPs in the region of HMGN3 gene formed a tightly combined haplotype block in both Chinese and Caucasians. The results suggest that the genomic region containing HMGN3 gene may be associated with spine BS in Chinese. (PMID:21947420)
• HMGN3 represses transcription of epithelial regulators to promote migration of cholangiocarcinoma in a SNAI2-dependent manner. (PMID:35635715)
• WTAP dysregulation-mediated HMGN3-m6A modification inhibited trophoblast invasion in early-onset preeclampsia. (PMID:36412513)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	hmgn6	ENSDARG00000087636
mus_musculus	Hmgn3	ENSMUSG00000066456
rattus_norvegicus		ENSRNOG00000073426

Paralogs (3): HMGN4 (ENSG00000182952), HMGN2 (ENSG00000198830), HMGN1 (ENSG00000205581)

Protein

Protein identifiers

High mobility group nucleosome-binding domain-containing protein 3 — Q15651 (reviewed: Q15651)

Alternative names: Thyroid receptor-interacting protein 7

All UniProt accessions (6): Q15651, A0A087WZE9, A0A994J3W4, A0A9L9PXC9, A0A9L9PXD4, A0A9L9PY81

UniProt curated annotations — full annotation on UniProt →

Function. Binds to nucleosomes, regulating chromatin structure and consequently, chromatin-dependent processes such as transcription, DNA replication and DNA repair. Affects both insulin and glucagon levels and modulates the expression of pancreatic genes involved in insulin secretion. Regulates the expression of the glucose transporter SLC2A2 by binding specifically to its promoter region and recruiting PDX1 and additional transcription factors. Regulates the expression of SLC6A9, a glycine transporter which regulates the glycine concentration in synaptic junctions in the central nervous system, by binding to its transcription start site. May play a role in ocular development and astrocyte function.

Subunit / interactions. Interacts with the ligand binding domain of the thyroid receptor (TR) (in vitro). Requires the presence of thyroid hormone for its interaction. Interacts with transcriptional regulator SEHBP. Interacts with nucleosomes.

Subcellular location. Nucleus.

Tissue specificity. Expressed in kidney, lung, pancreas, testis, skeletal muscle, heart, thyroid gland, pituitary gland, prostate and uterus. Low expression in liver, spleen, placenta and ovaries.

Induction. By estrogen.

Similarity. Belongs to the HMGN family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q15651-1	1, HMGN3a	yes
Q15651-2	2, HMGN3b

RefSeq proteins (9): NP_001188291, NP_001188292, NP_001305813, NP_001305814, NP_001305815, NP_001305816, NP_001305817, NP_004233, NP_620058 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000079	HMGN_fam	Family

Pfam: PF01101

UniProt features (12 total): compositionally biased region 4, modified residue 4, splice variant 2, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15651-F1	65.46	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 6, 10, 78, 93

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 273 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, RNGTGGGC_UNKNOWN, EFC_Q6, PUJANA_CHEK2_PCC_NETWORK, OUELLET_OVARIAN_CANCER_INVASIVE_VS_LMP_UP, BILD_HRAS_ONCOGENIC_SIGNATURE, FOSTER_TOLERANT_MACROPHAGE_UP, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, MODULE_301, HFH8_01, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, COATES_MACROPHAGE_M1_VS_M2_UP, SCHAEFFER_SOX9_TARGETS_IN_PROSTATE_DEVELOPMENT_UP, SCHLOSSER_SERUM_RESPONSE_DN

GO Biological Process (5): chromatin organization (GO:0006325), regulation of transcription by RNA polymerase II (GO:0006357), transcription by RNA polymerase II (GO:0006366), positive regulation of transcription by RNA polymerase II (GO:0045944), regulation of insulin secretion involved in cellular response to glucose stimulus (GO:0061178)

GO Molecular Function (5): chromatin binding (GO:0003682), nucleosomal DNA binding (GO:0031492), nuclear thyroid hormone receptor binding (GO:0046966), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
transcription by RNA polymerase II	2
binding	2
cellular component organization	1
regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
insulin secretion involved in cellular response to glucose stimulus	1
regulation of insulin secretion	1
regulation of cellular localization	1
chromatin DNA binding	1
nucleosome binding	1
nuclear receptor binding	1
nucleic acid binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1

Protein interactions and networks

STRING

536 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HMGN3	SLC6A9	P48067	894
HMGN3	CCNT2	O60583	773
HMGN3	THRB	P10828	726
HMGN3	HMGN5	P82970	579
HMGN3	TXNRD2	Q9NNW7	548
HMGN3	H1-0	P07305	506
HMGN3	SLC6A5	Q9Y345	497
HMGN3	AHCTF1	Q8WYP5	478
HMGN3	RXRA	P19793	462
HMGN3	HSPB3	Q12988	428
HMGN3	SRY	Q05066	428
HMGN3	H4C16	P02304	416
HMGN3	ZBTB8B	Q8NAP8	404
HMGN3	NR3C1	P04150	383
HMGN3	ZBTB16	Q05516	362

IntAct

26 interactions, top by confidence:

A	B	Type	Score
SRPK2	HMGN3	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
SRPK1	HMGN3	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
GRB2	HMGN3	psi-mi:“MI:0915”(physical association)	0.400
STUB1	HMGN3	psi-mi:“MI:0915”(physical association)	0.400
CCDC185	HMGN3	psi-mi:“MI:0915”(physical association)	0.400
S100A10	HMGN3	psi-mi:“MI:0915”(physical association)	0.400
H2BC12L	HMGN3	psi-mi:“MI:0915”(physical association)	0.400
H2BC9	HMGN3	psi-mi:“MI:0915”(physical association)	0.400
PRRC2C	HMGN3	psi-mi:“MI:0915”(physical association)	0.400
HMGN3	ANXA2	psi-mi:“MI:0915”(physical association)	0.400
MYO9B	HMGN3	psi-mi:“MI:0915”(physical association)	0.400
AHCTF1	HMGN3	psi-mi:“MI:0915”(physical association)	0.400
ZC3H4	HMGN3	psi-mi:“MI:0915”(physical association)	0.400
HMGN3	TERF1	psi-mi:“MI:0915”(physical association)	0.370
HMGN3	TERF2	psi-mi:“MI:0915”(physical association)	0.370
HMGN3	TERF2IP	psi-mi:“MI:0915”(physical association)	0.370
Csnk1d	WWP2	psi-mi:“MI:0914”(association)	0.350
APP	ESYT2	psi-mi:“MI:0914”(association)	0.350
RAB5A	PSMD14	psi-mi:“MI:0914”(association)	0.350
ACKR3	PDE2A	psi-mi:“MI:0914”(association)	0.350
SLC25A21	HMGN3	psi-mi:“MI:0914”(association)	0.350
	EBAG9	psi-mi:“MI:0914”(association)	0.350
NIN	ARPC3	psi-mi:“MI:2364”(proximity)	0.270
SMAD2	HMGN3	psi-mi:“MI:0915”(physical association)	0.000
HMGN3		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (69): HMGN3 (Proximity Label-MS), HMGN3 (Affinity Capture-MS), HMGN3 (Affinity Capture-MS), HMGN3 (Affinity Capture-MS), ZC3H4 (Proximity Label-MS), HMGN3 (Proximity Label-MS), CCDC185 (Proximity Label-MS), STUB1 (Proximity Label-MS), HMGN3 (Proximity Label-MS), HMGN3 (Proximity Label-MS), PRRC2C (Proximity Label-MS), HMGN3 (Proximity Label-MS), AHCTF1 (Proximity Label-MS), HIST1H2BH (Proximity Label-MS), HMGN3 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GTR3, O00479, O14598, P02313, P02314, P02315, P02316, P05114, P05204, P09602, P0DPH9, P10156, P12274, P12902, P18437, P18608, P22058, P49342, P80272, Q04504, Q15651, Q29026, Q2YDK4, Q32N87, Q32PF3, Q3ZBV4, Q4VC05, Q5FVI4, Q5R715, Q5RAA0, Q5RCI9, Q5XXA9, Q5ZIR5, Q5ZM33, Q66H40, Q6P8I4, Q711A6, Q80XU3, Q8C551, Q8N111

Diamond homologs: O00479, P02313, P02314, P05204, P09602, P12902, P18437, P80272, Q15651, Q2YDK4, Q3ZBV4, Q5R715, Q5RAA0, Q66H40, Q711A6, Q9DCB1, P02316, P05114, P12274, P18608, P82970, Q5ZIR5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 29 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Packaging Of Telomere Ends	5	43.9×	2e-05
Recognition and association of DNA glycosylase with site containing an affected purine	5	40.8×	2e-05
Cleavage of the damaged purine	5	40.8×	2e-05
Recognition and association of DNA glycosylase with site containing an affected pyrimidine	5	36.8×	2e-05
Cleavage of the damaged pyrimidine	5	36.8×	2e-05
Inhibition of DNA recombination at telomere	5	33.6×	2e-05
DNA Damage/Telomere Stress Induced Senescence	5	32.6×	2e-05
Meiotic synapsis	5	28.2×	3e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

27 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	14
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

978 predictions. Top by Δscore:

Variant	Effect	Δscore
6:79202386:CTTT:C	acceptor_gain	1.0000
6:79202390:C:CC	acceptor_gain	1.0000
6:79202402:C:CT	acceptor_gain	1.0000
6:79202407:CACAG:C	acceptor_gain	1.0000
6:79203574:TCTTA:T	donor_loss	1.0000
6:79203575:CTTAC:C	donor_loss	1.0000
6:79203576:TTACC:T	donor_loss	1.0000
6:79203577:TA:T	donor_loss	1.0000
6:79203578:A:AG	donor_loss	1.0000
6:79214967:CTTA:C	donor_loss	1.0000
6:79214968:TTA:T	donor_loss	1.0000
6:79214969:TACCT:T	donor_loss	1.0000
6:79214970:A:AC	donor_gain	1.0000
6:79214970:A:AT	donor_loss	1.0000
6:79214970:ACCT:A	donor_gain	1.0000
6:79214970:ACCTC:A	donor_gain	1.0000
6:79214971:C:CA	donor_loss	1.0000
6:79214971:C:CC	donor_gain	1.0000
6:79214971:CCT:C	donor_gain	1.0000
6:79214971:CCTC:C	donor_gain	1.0000
6:79214971:CCTCC:C	donor_gain	1.0000
6:79215021:GA:G	acceptor_gain	1.0000
6:79215023:C:CC	acceptor_gain	1.0000
6:79234541:CTTA:C	donor_loss	1.0000
6:79234542:TTACC:T	donor_loss	1.0000
6:79234543:TA:T	donor_loss	1.0000
6:79234544:A:AC	donor_gain	1.0000
6:79234544:ACCTT:A	donor_loss	1.0000
6:79234545:C:CC	donor_gain	1.0000
6:79234545:C:CG	donor_loss	1.0000

AlphaMissense

823 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:79208568:T:A	R25S	0.989
6:79208568:T:G	R25S	0.989
6:79208556:T:A	R29S	0.983
6:79208556:T:G	R29S	0.983
6:79234549:T:A	R4S	0.983
6:79234549:T:G	R4S	0.983
6:79208569:C:G	R25T	0.975
6:79208554:A:G	L30S	0.968
6:79208557:C:G	R29T	0.965
6:79234550:C:G	R4T	0.962
6:79208569:C:A	R25I	0.959
6:79208558:T:C	R29G	0.958
6:79208570:T:C	R25G	0.946
6:79234550:C:A	R4I	0.941
6:79208554:A:C	L30W	0.933
6:79234552:C:A	K3N	0.930
6:79234552:C:G	K3N	0.930
6:79208557:C:A	R29I	0.926
6:79208566:C:G	R26P	0.914
6:79234546:C:A	K5N	0.905
6:79234546:C:G	K5N	0.905
6:79203601:T:A	K42N	0.898
6:79203601:T:G	K42N	0.898
6:79208563:G:A	S27F	0.897
6:79208567:G:C	R26G	0.893
6:79234556:G:A	P2L	0.891
6:79234553:T:A	K3M	0.886
6:79208566:C:A	R26L	0.864
6:79208575:G:T	P23H	0.864
6:79203628:T:A	K33N	0.847

dbSNP variants (sampled 300 via entrez): RS1000067376 (6:79211033 A>T), RS1000081822 (6:79217807 T>C,G), RS1000138877 (6:79212378 A>T), RS1000175606 (6:79218000 T>C), RS1000295568 (6:79224046 T>C), RS1000397302 (6:79210593 G>A), RS1000414257 (6:79230071 A>G), RS1000420201 (6:79224824 G>T), RS1000438944 (6:79205443 A>G), RS1000486589 (6:79230378 T>A,C), RS1000487104 (6:79215806 A>G), RS1000489708 (6:79205671 G>T), RS1000518092 (6:79216144 G>C), RS1000597428 (6:79222277 T>C), RS1000746183 (6:79228759 G>A,T)

Disease associations

OMIM: gene MIM:604502 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002726_61	Glucose homeostasis traits	1.000000e-06
GCST009614_2	LDL cholesterol levels x loop diuretics use interaction	4.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004471	insulin sensitivity measurement
EFO:0004611	low density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, increases expression	4
sodium arsenite	decreases expression, increases expression	3
Air Pollutants	increases abundance, decreases expression, affects expression	3
Valproic Acid	affects expression, decreases methylation, increases expression	3
Cyclosporine	decreases expression	3
cobaltous chloride	decreases expression	2
Doxorubicin	increases expression, affects response to substance	2
Ozone	affects expression, increases abundance, decreases expression, increases oxidation	2
Quercetin	decreases expression	2
Tretinoin	decreases expression, increases expression	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
dicrotophos	decreases expression	1
dimethylselenide	decreases expression, increases oxidation	1
beta-lapachone	decreases expression	1
arsenite	affects binding, increases reaction	1
methylparaben	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
epigallocatechin gallate	decreases expression, affects cotreatment	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
bisphenol S	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Leflunomide	decreases expression	1
Acetaminophen	decreases expression	1

Cellosaurus cell lines

4 cell lines: 3 embryonic stem cell, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A2T8	SEES3-1V human HMGN3, clone1	Embryonic stem cell	Male
CVCL_A2T9	SEES3-1V human HMGN3, clone2	Embryonic stem cell	Male
CVCL_A2U0	SEES3-1V human HMGN3, clone3	Embryonic stem cell	Male
CVCL_B2YV	Abcam HEK293T HMGN3 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.